==== Front IDCases IDCases IDCases 2214-2509 Elsevier S2214-2509(18)30078-7 10.1016/j.idcr.2018.e00422 e00422 Article Nocardia paucivorans brain abscess. Clinical and microbiological characteristics Aliaga Luis laliaga@ugr.es ab⁎ Fatoul Georgette b Guirao-Arrabal Emilio b Peña Alejandro c Rodríguez-Granger Javier d Cobo Fernando d a Department of Medicine, University of Granada, Avda. de la Ilustración, 80, 18016, Granada, Spain b Department of Internal Medicine. Hospital Campus de la Salud, Avda. de la Ilustración, 80, 18016, Granada, Spain c Department of Microbiology, Hospital Campus de la Salud, Avda. de la Ilustración, 80, 18016, Granada, Spain d Department of Microbiology, Hospital Virgen de las Nieves, Avda. de las Fuerzas Armadas, s/n, 18014, Granada, Spain ⁎ Corresponding author at: Department of Medicine, University of Granada, Avda. de la Ilustración, 80, 18016, Granada, Spain. laliaga@ugr.es 04 7 2018 2018 04 7 2018 13 44 16 4 2018 2 7 2018 2 7 2018 © 2018 The Authors 2018 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Highlights • Brain abscess caused by Nocardia paucivorans is an infrequent infection in humans. • Molecular speciation has revolutionized the study of Nocardia spp. infections. • N. paucivorans brain abscess has a favourable prognosis with long-term antimicrobial therapy. • Antimcirobial susceptibility testing is a useful guide to therapy. Nocardia paucivorans brain abscesses are unusual in humans. Sixteen cases of this infection have been reported in the world medical literature. There is precise clinical information available from nine patients. All of these patients recovered or were cured from their brain disease with long-term antimicrobial treatment. Surgical drainage was performed in four patients. Keywords Nocardia Nocardiosis Nocardia paucivorans Nocardia brain abscess Nocardia infections ==== Body Introduction Nocardia species are ubiquitous in nature and mainly cause pulmonary disease in humans; but It can also infect the central nervous system and the skin [1,2]. Traditional phenotypic laboratory methods for identification of Nocardia species are limited in their ability to differentiate these organisms. Instead, various molecular techniques have been developed which allow accurate species determination [1]. The identification of clinical isolates to the species level is crucial to characterize associated disease manifestations, predict antimicrobial susceptibiltiy and identify differences in epidemiology. In 2000, Yassin et al. [3] described a new species of the genus Nocardia based on chemotaxonomic and molecular analysis of an isolate from the respiratory secretions of a patient with chronic lung disease, which was called Nocardia paucivorans. We have recently studied a patient with a brain abscess caused by N. paucivorans. The literature has provided limited guidance regarding the care of patients with this condition [[4], [5], [6], [7], [8], [9], [10], [11], [12]]. Thus, a review of this topic seems timely. Case report A 61-year-old man was admitted to the hospital because of a 2-week history of progressive right hemiplegia and frontal headache. He had been diagnosed of ocular myasthenia gravis two years before and received medication with pyridostigmine, and prednisone (10 mg/day). At presentation, physical examination revealed right hemiplegia and his temperature was 36.5 °C. Laboratory investigations were unremarkable. A CT scan of the head showed a left frontal lesion suggestive of metastasis. A CT scan of the chest, abdomen and pelvis did not show abnormalities. A cerebral magnetic resonance imaging (MRI) disclosed a multiloculated necrotic cystic ring enhancing lesion in the left frontal area, with surrounding edema. Diffusion-weighted imaging showed restriction of the diffusion. Stereotactic aspiration of the left frontal lesion was performed, obtaining twelve mL of purulent fluid. A Gram-stained smear of the fluid showed branching, filamentous Gram-positive bacilli, which were further identified, after growth in culture, as N. paucivorans by means of 16S rRNA sequence analysis. Susceptibility was determined by E-test method. The organism was susceptible to trimethoprim-sulfamethoxazole (TMP-SMX), amikacin, amoxicillin-clavulanate, cefotaxime, ceftriaxone, levofloxacin, linezolid and tigecycline; and was resistant to imipenem, clarithromycin, and clindamycin. Tests for human immunodeficiency virus (HIV) types 1 and 2 antibody and p24 antigen were negative. The patient was initially treated with ceftriaxone (2 g IV q12 h) and TMP-SMX intravenously (15 mg/kg/day of TMP in four divided doses). Because the patient developed unremitting vomiting, TMP-SMX was changed to linezolid (600 mg IV q12 h) and after completion of 6 weeks, the patient continued taking levofloxacin (500 mg po/day) for 10 months. At six months of treatment, the patient recovered strenght in the right extremities and he was able to walk by himself. A MRI showed disappearance of the brain abscess. Discussion Standard phenotype-based identification methods for Nocardia species are slow and often imprecise. Therefore, various nucleic acid amplification tools targeting conserved gene regions have been used to provide rapid and accurate species determination. Of these tools, 16S rRNA gene sequence analysis is the most fequently used and has become “the gold standard” method for definitive species identification [1]. We performed 5′ end 16S rRNA gene PCR targeting the first 500-bp of the gene. There is consensus that this region contains sufficient sequence variability for species identification [1]. N. paucivorans has seldom been isolated from humans. In Queensland, an Australian state with a population of 3.66 million people, all nocardia isolated were identified to the species level between 1985 and 2004. Only 33 patient strains were characterized as N. paucivorans among approximately 1800 isolates of Nocardia species [7]. Using the MEDLINE database back to the year 2000, we found sixteen cases of brain abscess caused by N. paucivorans in the world medical literature [[4], [5], [6], [7], [8], [9], [10], [11], [12]]. The clinical features of the sixteen patients and the one described herein are summarized in Table 1. The average age of the patients was 59 years (range 40–80 years) and 81% were male. There are brain imaging findings available from nine patients. Single ring-enhancing lesions were observed in four patients and multiple lesions in five patients. The infection was primary in the Central Nervous System (CNS) in ten patients. Six cases also had pneumonia in addition to CNS disease. The organism was identified from samples of the CNS in eight patients and from samples outside the CNS in three cases. No information is available on the remaining six patients.Table 1 Characteristics of the 17 patients with Nocardia paucivorans brain abscess. Table 1Case nº., [Reference] Age (yr)/ Sex Concomitant illnesses or condition Location of infection Symptom(s) and sign(s) Brain imaging findingsa Source of Identification of Nocardia Treatment Outcome 1 [4] 63/M Low CD4+ T-cell count, HIV negative, cerebellar abscess removed 6 mo before Cerebellar mass, meningitis Headache, singultus Cerebellar mass with surrounding edema CSF Cef + Amp (3 d); Amk + Mer (6 w); Levo + Mino (12 mo) Neurological symptoms improved. No change in MRI findings 2 [5] 40/F NR Brain abscesses NR NR Brain biopsy NR NR 3 [6] 63/M Hypertension Bain abscess Apathy Right frontal lobe multi-loculated ring-enhancing lesion with vasogenic edema and mass effect Purulent material from brain lesion Craniotomy and pus removed. TMP-SMX (4 mo) Complete resolution of brain CT scan after 4 mo of antibiotics 4 [7] 53/M Cigarette smoker, hepatitis C virus infection Pneumonia, brain abscess, arm lesion Cough, sputum, nausea, cachexia, ataxia, tender skin lesion Multiple ring-enhancing brain lesions with surrounding edema BAL fluid, skin lesion TMP-SMX (12 mo) Clinical and radiological resolution. No relapse after 12 mo of stopping antibiotics. 5 [7] 55/M NR Brain abscess NR NR NR NR NR 6 [7] 41/M Hodgkin’s disease Brain abscess NR NR NR NR NR 7 [7] 58/F Corticosteroid therapy Brain abscess NR NR NR NR NR 8 [7] 54/M None Endocarditis, brain abscess, hand lesion NR NR Blood, hand lesion NR NR 9 [7] 66/M Immunosuppressed Brain abscess NR NR Brain tissue NR NR 10 [7] 57/M NR Brain abscess, pneumonia NR NR Lung, brain lesion NR NR 11 [7] 67/M Diabetes mellitus Brain abscess NR NR NR NR NR 12 [8,9] 50/M Cigarette smoker Brain abscesses, pneumonia, mediastinal lymph nodes, iliopsoas muscle Headache, vomiting, cough, confusion, nuchal rigidity, slight upper monoparesia, cachexia Multiple ring-enhancing brain lesions Subcarinal lymph node TMP-SMX + Imi (2 w); TMP-SMX + Imi + Line + dexamethasone (3 w); TMP-SMX + Moxi (4 mo); Moxi (7 mo) Resolution of brain and pulmonary lesions. Complete neurological recovery. 13 [10] 70/M Multiple myeloma, lenalidomide and dexamethasone therapy Brain abscesses, pneumonia Seizures Six ring-enhancing brain lesions with surrounding edema Brain biopsy TMP-SMX + Mer (3 w); Cip (12 mo) Complete resolution of brain lesions on CT scan. No relapse of seizure. 14 [11] 54/M Right pneumonia two mo before Cerebellar abscess NR Ring-enhancing cerebellar lesion and hydrocephalus Cerebellar biopsy Abscess drainage and EVD. Cef + Met (2 w); Line + Mer (1 w); Line + Imi (7 w); Cef + Met + Mer (2 w); Van + Rif + Mer (2 w); Van + Rif + Cef + TMP-SMX (2 w); Cef + TMP-SMX + Line (2 mo); Cef + TMP-SMX + Rif (5 w); TMP-SMX + Line (4 w); TMP-SMX (11 w) Development of ventriculitis while on antibiotic treatment. Ventriculoperitoneal shunting required. Asymptomatic 8 mo after stopping antibiotics. 15 [12] 80/F None Brain, lung Right hemiparesis, memory impairment Multiple ring-enhancing brain lesions NR Surgery. Cef + TMP-SMX (35 d); TMP-SMX (9 mo) Cured at 1 yr of follow-up 16 [12] 59/M None Brain, lung Headache, confusion Multiple ring-enhancing brain lesions and hydrocephalus NR EVD. Mer + TMP-SMX (2 mo); TMP-SMX (12 mo) Recovered with neurologic sequelae at 1 yr of follow-up 17 [PR] 63/M Ocular myasthenia gravis. corticosteroids therapy Brain abscess Headache, right hemiplegia Left frontal lobe multiloculated ring-enhancing lesion Stereotactic abscess aspiration Abscess aspiration. TMP-SMX + Cef + Met (3 d); TMP-SMX + Cef (2 w); Line + Cef (6 w); Levo (10 mo). Recovered, with minimal sequelae. Abbreviations: Amk = amikacin; Amp= Ampicillin; BAL = bronchoalveolar lavage; Cef = ceftriaxone; CSF = cerebrospinal fluid; Cip = ciprofloxacin; d = days; EVD = external ventricular drain; Imi = imipenem; Levo = levofloxacin; Line = linezolid; Mer = meropenem; Met = metronidazole; Mino = minocycline; mo = months; Moxi = moxifloxacin; NR = not repored; PR = present report; Rif = rifampin; TMP-SMX = trimethoprim-sulfamethoxazole; Van = vancomycin; w = weeks. a Brain imaging includes findings of brain CT scan and/or brain Magnetic Resonance Imaging. The most common predisposing factors for nocardiosis are corticosteroid use, organ transplantation, malignancy and HIV infection [1,2]. In this series, two patients had neoplasia, two patients received corticosteroids and two had unspecified immunosuppression. Six patients had no predisposing conditions. In contrast with previous studies [2], no patient was seropositive for HIV infection nor had been an organ transplant recipient. Clinical manifestations of eight patients are available. The most frequent symptoms at presentation were headache and altered mental status (in four patients each). Focal neurological deficits were observed in five patients. Two patients had hemiplegia, one patient had a slight right-sided pronator drift and one had ataxia. One individual presented with seizures. Nuchal rigidity was noted in one instance. Fever was not registered in any case. The duration of symptoms was documented in six patients, and had an average duration of 12.8 days (from immediate onset to one month). Of the nine patients for whom details about treatment are reported, eight received treatment with regimens including TMP-SMX, in combination with other antimicrobials in six patients. Therapeutic regimens lasted between 4 and 14 months. Four patients were treated only with antibacterials with resolution of the cerebral lesion. Surgery was undertaken in four patients (abscess removal in three patients; and aspiration in one patient). Complete clinical resolution was achieved in five patients. Four patients recovered from neurological clinical symptoms but with sequelae. Despite the high mortality rate reported in patients with cerebral nocardiosis, ranging from 31% to 55% [1,12], no patient died in our review. Optimal treatment regimens for Nocardia infections have not been established by controlled clinical trials [1]. Thus, treatment is based on case series and expert opinion. TMP-SMX is the mainstay of treatment of Nocardia, and it is the drug of choice for cerebral nocardiosis due to its good penetration in the CNS [1,2,12]. As empiric treatment, Rafiei et al. [12] recommended intravenous TMP-SMX plus meropenem for brain nocardiosis. Some authorities also advise a combination of drugs, including carbapenem derivatives, as induction therapy [2]. However, antimicrobial susceptibility testing is a useful guide to therapy in the setting of the newly described Nocardia species, when combination therapy is warranted, and in patients with TMP-SMX intolerance [1,13]. The Clinical and Laboratory Standards Institute has approved a broth microdilution method for antimicrobial testing of the aerobic actinomycetes and it is the reference method for Nocardia spp. [14]. Broth microdilution method, nonetheless, is somewhat impractical to many microbiology laboratories owing to cost, availability of supplies, and expertise needed to perform and interpret the results [15]. Other methods for Nocardia susceptibility testing include the E test and the BACTEC radiometric methods, which have been shown to correlate well with broth microdilution and are simpler to use in the routine clinical laboratory [15]. Antimicrobial susceptibility data available from N. paucivorans are scarce. Schlaberg et al. [13] have recently tested 11 strains of N. paucivorans. Nonsusceptibility (resistant or intermediate) were 90% for amoxicillin-clavulanic acid, 18% for clarithromycin, and 9% for ciprofloxacin and minocycline, respectively. All isolates tested were susceptible to TMP-SMX, amickacin, imipenem, ceftriaxone, tobramycin and moxifloxacin. In our review, there are available data on susceptibility testing from patient number 1, 2, 12, 13, 15, 16, and 17 (see Table 1). One patient showed intermediate resistance to amoxicillin-clavulanate (patient 16), three patients tested showed resistance to clarithromycin (patients 15, 16 and 17), and our patient showed resistance to imipenem. In recent years, linezolid has been included as an alternative to TMP-SMX, although adverse side effects should be considered for long-term therapy [2]. Interestingly, all Nocardia strains tested for linezolid are uniformly susceptible up to now [1,2,13]. There are no formal guidelines to define treatment duration; however, 12 months is commonly recommended by experts [1,2,12]. In conclusion, brain abscess caused by N. paucivorans is an infrequent disease in humans that may have a favourable prognosis with long-term antimicrobial treatment. Confict of interest None. Funding source None. Ethical approval Not required. Author statement The author agree with the recommendations and rules of the Journal (IDCases). On the other hand, all authors have contributed to the writing paper, have read it and agree with the content. ==== Refs References 1 Sorrell T.C. Mitchell D.H. Iredell J.R. Chen S.C.-A. Nocardia species 8th ed. Bennett J.E. Dolin R. Blaser M.J. Mandell, Douglas and Bennett’s principles and practice of infectious diseases Vol 2 2015 Elsevier Philadelphia 2853 2863 e2 2 Minero M.V. Marín M. Cercenado E. Rabadán P.M. Bouza E. Muñoz P. Nocardiosis at the turn of the century Medicine (Baltimore) 88 2009 250 261 19593231 3 Yassin A.F. Rainey F.A. Burghardt J. Brzezinka H. Mauch M. Schaal K.P. Nocardia paucivorans sp. nov Int J Syst Evol Microbiol 50 2000 803 809 10758891 4 Eisenblätter M. Disko U. Stoltenburg-Didinger G. Scherübl H. Schaal K.P. Roth A. Isolation of Nocardia paucivorans from the cerebrospinal fund of a patient with relapse of cerebral nocardiosis J Clin Microbiol 40 2002 3532 3534 12202613 5 Wellinghausen N. Pietzcker T. Kern W.V. Essig A. Marre R. Expanded spectrum of Nocardia species causing clinical nocardiosis detected by molecular methods Int J Med Microbiol 292 2002 277 282 12398218 6 Khan S.-N.H. Sanche S.E. Robinson C.A. Pirouzmand F. N. paucivorans infection presenting as a brain abscess Can J Neurol Sci 33 2006 426 427 17168173 7 Gray T.J. Serisier D.J. Gilpin C.M. Coulter C. Bowler S.J. McCormack J.G. Nocardia paucivorans- a cause of disseminated Nocardiosis J Infect 54 2007 e95 8 16808975 8 Hammoud M. Kraft C. Pulst-Korenberg J. Chenoweth C. Gregg K.S. Disseminated Nocardia paucivorans infection in an immunocompetent host Infection 42 2014 917 920 24634088 9 Delavari N. Than K.D. Chen K.S. McKeever P.E. Wang A.C. Pandy A.S. Resolution of innumerable cerebral Nocardia paucivorans abscesses after medical management J Clin Neurosci 27 2016 175 177 26765763 10 Monticelli J. Luzzati R. Maurel C. Rosin C. Valentinotti R. Farina C. Brain abscesses caused by Nocardia paucivorans in a multiple mieloma patient treated with Lenalidomide and Dexamethasone: a case report and review of literature Mediterr J Hematol Infect Dis 7 2015 e2015011 11 Schiaroli E. Pasticci M.B. De Carolis E. Mello E. Pallotto C. Leli C. Diagnosis of Nocardia paucivorans central nervous system infection by DNA sequencing from paraffin-embedded tissue Infez Med 24 2016 147 152 27367327 12 Rafiei N. Peri A.M. Righi E. Harris P. Paterson D.L. Central nervous system nocardiosis in Queensland. A report of 20 cases and review of the literature Medicine (Baltimore) 95 2016 e5255 27861348 13 Schlaberg R. Fisher M.A. Hanson K.E. Susceptibility profiles of Nocardia isolates based on current taxonomy Antimicrob Agents Chemother 58 2014 795 800 24247124 14 Woods G.L. Brown-Elliot B.A. Conville P.S. Desmond E.P. Hall G.S. Lin G. 2nd ed Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard vol 31 2011 Clinical and Laboratory Standards Institute Wayne PA CLSI document M24-A2 15 Jenkins S.G. Schuetz A.N. Current concepts in laboratory testing to guide antimicrobial therapy Mayo Clin Proc 87 2012 290 308 22386185